J Neurosurg. 2018 Aug;129(2):334-340. doi: 10.3171/2017.3.JNS162280. Epub 2017 Oct 20.
The detection of glioblastoma (GBM) in biofluids offers potential advantages over existing paradigms for the diagnosis and therapeutic monitoring of glial tumors. Biofluid-based detection of GBM focuses on detecting tumor-specific biomarkers in the blood and CSF. Current clinical research concentrates on studying 3 distinct tumor-related elements: extracellular macromolecules, extracellular vesicles, and circulating tumor cells. Investigations into these 3 biological classifications span the range of locales for tumor-specific biomarker discovery, and combined, have the potential to significantly impact GBM diagnosis, monitoring for treatment response, and surveillance for recurrence. This review highlights the recent advancements in the development of biomarkers and their efficacy for the detection of GBM.
在生物体液中检测神经胶质瘤（GBM）相对于现有的神经胶质肿瘤诊断和治疗监测模式具有潜在优势。基于生物体液的 GBM 检测侧重于检测血液和 CSF 中的肿瘤特异性生物标志物。当前的临床研究集中在研究 3 种不同的肿瘤相关因素：细胞外大分子、细胞外囊泡和循环肿瘤细胞。对这 3 种生物分类的研究涵盖了肿瘤特异性生物标志物发现的所有潜在位置，并且结合起来，有可能对 GBM 的诊断、治疗反应监测以及复发监测产生重大影响。本文综述了生物标志物的最新进展及其在检测 GBM 中的应用。
